Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Ellsworth Advisors LLC

Ellsworth Advisors LLC lifted its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.7% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 37,813 shares of the specialty pharmaceutical company’s stock after buying an additional 632 shares during the quarter. Ellsworth Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $4,213,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in Jazz Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock valued at $776,551,000 after buying an additional 84,941 shares during the period. LSV Asset Management raised its holdings in Jazz Pharmaceuticals by 4.2% during the second quarter. LSV Asset Management now owns 2,480,563 shares of the specialty pharmaceutical company’s stock worth $264,750,000 after purchasing an additional 99,705 shares in the last quarter. Pacer Advisors Inc. lifted its position in Jazz Pharmaceuticals by 40.7% in the second quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock valued at $194,346,000 after purchasing an additional 527,187 shares during the period. Capital World Investors purchased a new stake in Jazz Pharmaceuticals in the 1st quarter valued at approximately $171,943,000. Finally, Baupost Group LLC MA increased its position in Jazz Pharmaceuticals by 52.8% during the 2nd quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock worth $136,000,000 after purchasing an additional 440,552 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock opened at $114.63 on Friday. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $137.38. The company has a market capitalization of $7.23 billion, a price-to-earnings ratio of 23.64, a PEG ratio of 1.34 and a beta of 0.57. The stock has a fifty day moving average of $110.81 and a two-hundred day moving average of $109.82. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.02 and a current ratio of 2.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 EPS for the quarter, topping analysts’ consensus estimates of $3.80 by $0.87. The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. On average, analysts anticipate that Jazz Pharmaceuticals plc will post 16.03 EPS for the current fiscal year.

Insider Activity

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the sale, the senior vice president now owns 14,531 shares in the company, valued at approximately $1,573,707.30. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 4.20% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on JAZZ shares. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. UBS Group decreased their target price on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating on the stock in a research report on Tuesday, July 2nd. Royal Bank of Canada increased their price target on shares of Jazz Pharmaceuticals from $174.00 to $175.00 and gave the company an “outperform” rating in a report on Friday, October 4th. Needham & Company LLC reissued a “buy” rating and set a $205.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, September 10th. Finally, Robert W. Baird dropped their target price on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating for the company in a report on Thursday, August 1st. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $173.14.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.